7 hours ago, vememah said:

 

 

Ovo je dobra vest, mada je ovo skromna cifra. Ne bi bilo lose da jos neko upadne u ovu pricu. Mozda Merck, posto su i oni odustali od svoje vakcine? 

63 od 428k u Izraelu je veoma ohrabrujuce. Onih 95% efikasnosti sada izgleda mnogo realnije.

Quote

 

Johnson & Johnson Expects to Report Covid-19 Vaccine Results by Next Week

Company expects to deliver 100 million doses for U.S. use by end of June if regulators authorize its shot

 

 

gazi!

On 25.1.2021. at 22:49, borris_ said:

Treba vidjeti kako radi ova kineska.

 

Saznaćemo uskoro.

5 hours ago, Moracikus said:

63 od 428k u Izraelu je veoma ohrabrujuce. Onih 95% efikasnosti sada izgleda mnogo realnije.

 

I sami Izraelci kažu da su zadovoljni:

 

 

Quote

 

#WarOnCovid

What the world can learn about immunity from Israel’s vaccine rollout

Israel's extraordinary vaccination program has provided a wealth of information about the Pfizer-BioNTech vaccine and it's impact.

By Abigail Klein Leichman  JANUARY 27, 2021, 7:00 AM

 

 

More than 1.3 million Israelis have already received both doses of the Covid-19 vaccine from Pfizer-BioNTech.

The extraordinarily fast and organized vaccination campaign in Israel is unmatched per capita anywhere in the world.

 

By design, this fast rollout is providing Pfizer – and the rest of us – with the first critical real-world data on brand-new mRNA vaccines.

This type of vaccine instructs cells to make a “spike” protein that triggers the immune system to produce antibodies against the matching spike protein on the surface of the SARS-CoV-2 coronavirus, which causes Covid-19.

“Pfizer knows the data they will get from Israel is good and accurate. They see our rate of vaccination is very efficient so they can report post-marketing data to the FDA quickly,” says microbiology expert Dr. Natan Keller, vice-chairman of Sheba Medical Center’s Institutional Review Board Committee and past president of the Israeli Society of Infectious Diseases.

FDA emergency use approval for the Pfizer vaccine was based on a study of 24,000 vaccine recipients and 24,000 placebo recipients, says Keller.

Israel now has data from more than 2.7 million who got at least one dose and the number increases by about 100,000 per day.

ISRAEL21c gathered information from local experts and national health-maintenance organizations (HMOs) on what Israel has learned about the vaccine and its efficient distribution.

We will continue to keep you updated as new data emerges, and as the Moderna mRNA vaccine comes into use in Israel.

VACCINE EFFECTIVENESS

What we know

Pfizer-BioNTech’s studies showed the mRNA vaccines to be about 95 percent effective within a certain amount of time after the second dose.

“We know Pfizer’s data was quite accurate,” says Keller. “Effectiveness is in the high 90s after the second dose — Pfizer says eight days, but I recommend 14 days for full immunity.”

Studies from the Clalit and Maccabi HMOs support Keller’s recommendation. Even so, Maccabi saw a 60% drop in Covid-19 hospitalizations among members aged 60 and over as little as two days after the second dose.

“Based on our data, we know most people infected after the first dose were infected within the first two weeks of vaccination,” says Keller. “We also know that statistically, the disease is less severe in the vaccinated [even one dose] than in the non-vaccinated.”

Indeed, Maccabi reported that although 20 members got infected with Covid-19 after the second dose — out of 128,600 in total – they experienced only mild symptoms and recovered at home.

Also encouraging was a Sheba study that found employees who received both doses had more antibodies against the novel coronavirus than did recovered Covid-19 patients.

What we don’t know

“For now, nobody knows how long the vaccine protects,” says Keller. “We may need updated vaccines every year or two.”

Dr. Gili Regev-Yochay, director of Sheba’s Infectious Disease Epidemiology Unit, and her staff will follow up for more than a year with vaccinated volunteers to continue studying the interaction between the virus and the vaccine.

Regev-Yochay said it is unlikely that vaccinated people can still spread the SARS-CoV-2 virus to others, but that’s not yet proven.

Nor is there scientific data supporting some countries’ decision to delay administration of the second dose due to high morbidity and vaccine shortages.

“Waiting longer might be better, the same, or it could be worse,” says Ella Sklan, PhD, of Tel Aviv University medical school’s department of clinical immunology and microbiology.

“Since 21 days between doses in the Pfizer trials and 28 days in the Moderna trials were the only conditions tested and proved efficient, any deviation from these schedules is an experiment,” Sklan tells ISRAEL21c.

“That’s why most health agencies do not recommend delaying the second dose. However, for other vaccines, though with different mechanisms of action, you can give the second dose half a year later and they work fine.”

SIDE EFFECTS

“Israel’s public health system has special software developed years ago for very efficient vaccination logistics and follow-up on side effects,” says Keller.

“In general, vaccine side effects are extremely rare. With the Covid vaccine, mostly people have been reporting minor side effects from the first dose when they come for the second dose,” he says.

These effects are mainly soreness or pain at the injection site in the arm, which passes after a day or so.

“This comprehensive data is from medical staff or people above age 60, so we know most of the real side effects and it seems quite safe including minor side effects,” concludes Keller.

VACCINE VS. MUTATIONS

“Right now, the virus has infected almost 100 million people in the world and that creates a lot of chances for mutations to emerge,” says Sklan.

However, she adds, “We see only one to two mutations in the SARS-CoV-2 virus genome per month — which is not a lot compared to other viruses. Most mutations don’t cause any recognizable change in the virus and some actually harm the virus. It’s rare that a mutation gives a virus an advantage.”

She and Keller agree with experts who assume that the existing vaccines will be effective against most new variants.

“The mRNA vaccines [from Pfizer and Moderna] contain the sequence coding the spike protein — a large protein made up of 1,273 amino acids in a 3-dimensional structure,” Sklan explains.

“The antibody response generated by the vaccine is against multiple areas on the spike protein. Thus, if there are mutations, for example in 10 amino acids, we assume it will have some impact on the effectiveness but will not completely block the ability of the antibodies to neutralize the virus. In addition, aside from antibodies, we have other immune components that can attack the virus as well.”

HERD IMMUNITY

Achieving herd immunity — indirect protection that occurs when a sufficient percentage of a population has immunity — depends on the number of infections in a community and other factors, says Sklan.

“But it will be difficult to stop infections if a large proportion of the population, such as children, are not vaccinated,” she adds.

Pfizer’s vaccine is approved for ages 16 and over; Israel has started vaccinating 16- to 18-year-olds. The pharma company is now doing trials on 12- to 16-year-olds. The Israeli government may be the first country to consider vaccinating children under 16 who are at high risk of if they get infected. For now, Sklan says, no vaccine developer is testing in children under 12.

“The only thing we can do, until the vaccine is approved for younger age groups, is get as many people as possible vaccinated in the age group that can get it, because that will lower the number of infections in the general population, the number of severe Covid-19 patients and the probability of the emergence of new variants.”

Israel’s Health Ministry is now advising pregnant women to [get] vaccinated, citing several severe Covid-19 cases in pregnant women and “no evidence of harm resulting from vaccination during the entire pregnancy.”

Dr. Ran Balicer, epidemiologist and chief innovation officer for Clalit Health Services, and an adviser to the World Health Organization, recently tweeted, “If we can reach 60% [vaccination] coverage by March, viral transmission will likely be heavily disrupted and transmission dynamics considerably changed for the better.”

VACCINATION LOGISTICS

SYN-RG-Ai Integrative Solutions used its expertise in crisis management to help Israeli government agencies accomplish a swift and efficient rollout of the Covid vaccines.

“Israel’s vaccine campaign was so successful because the Israeli government used the day-to-day apparatus of our HMO system that touches every citizen,” says Col. (Ret.) Avi Cohen, cofounder of SYN-RG-Ai.

“Great logistics won’t help if people don’t come,” he tells ISRAEL21c. “In Israel there are few who do not want to take the vaccine, compared to 40% in some European countries.”

Full research and clinical data from Pfizer and Moderna were provided to primary-care physicians in the HMOs. These physicians were the first to get vaccinated as an example to their patients.

Logistics were adjusted for each place. For example, in towns with inadequate transportation options, minibuses were available to take people to the nearest city to get vaccinated.

SYN-RG-Ai is advising several foreign governments and hopes to bring the Israeli model to other major cities, states and nations.

Cohen advises every country to put vaccination logistics into the hands of trusted organizations that work closely with citizens day to day, such as community volunteer groups.

“If you operate through the strongest and most trusted such group in each area, it works,” Cohen says.

LOOKING AHEAD

Even as more data comes in on the effectiveness of Covid-19 vaccines, Sheba’s Keller says preventive measures of masks, social distancing and handwashing remain essential.

“Because there are always some people who will not get vaccinated — or who cannot get vaccinated for medical reasons including that they are under 16 or in chemotherapy, or immune deficient — it is very important not to stop taking precautions for many months,” he says. “We have a responsibility to protect them too.”

Clalit’s Balicer added that precautions also are necessary because no Covid-19 vaccine is 100 percent effective. “There is no complete protection,” he said.

 

 

https://www.israel21c.org/what-the-world-can-learn-from-israels-fast-vaccine-rollout/

Edited January 27, 20215 yr by vememah

Regeneron terapija antitelima kojom je lečen Tramp više od mesec dana pre nego što je odobrena u SAD košta 2 soma evritja po dozi i kažu da deluje i protiv novih varijanti virusa.

 

Quote

 

Regeneron says study shows its monoclonal antibody cocktail works against coronavirus variants

Tests on two different variants of the coronavirus show that one of the two monoclonal antibodies in Regeneron's cocktail therapy can neutralize both, despite the mutations, researchers reported Wednesday.

The tests also confirm what other teams of researchers have found: vaccines are likely to protect people against both the variant first seen in Britain and known as B.1.1.7, and one first noted in South Africa and called B.1.135. However, the mutations in B.1.135 do allow the virus to evade immune responses a little more, the team, led by Dr. David Ho at Columbia University's Aaron Diamond AIDS Research Center, reported in a pre-print report -- one not yet published in a peer-reviewed journal.

Regeneron's cocktail has been granted emergency use authorization by the US Food and Drug Administration, and it was used to treat former president Donald Trump when he was infected with coronavirus last year.

"As we expected, the virus continues to mutate, and these data show the continued ability of REGEN-COV to neutralize emerging strains, further validating our multi-antibody cocktail approach to infectious diseases," Regeneron president Dr. George Yancopoulos said in a statement.

"With two complementary antibodies in one therapeutic, even if one has reduced potency, the risk of the cocktail losing efficacy is significantly diminished, since the virus would need to mutate in multiple distinct locations to evade both antibodies."

Ho's team tested convalescent plasma from 20 patients who recovered from Covid-19, and also blood from 22 people who got two doses of either Pfizer's or Moderna's coronavirus vaccines. They also tested Eli Lilly and Company's single monoclonal antibody treatment, which also has an EUA.

The mutations in B.1.1.7 had small effects, if any. But one mutation especially, in B.1.135, did reduce the efficacy of the immune response in convalescent plasma, in both vaccines, of one of Regeneron's antibodies and of Lilly's antibody, they said.

The same mutation is found in a variant first seen in Brazil.

"Mutationally, this virus is traveling in a direction that could ultimately lead to escape from our current therapeutic and prophylactic interventions directed to the viral spike," Ho's team wrote.

"If the rampant spread of the virus continues and more critical mutations accumulate, then we may be condemned to chasing after the evolving SARS-CoV-2 continually, as we have long done for influenza virus."

This means the world must vaccinate people faster and, in the meantime, double down on measures to stop the spread of virus, such as mask use, they said.

 

https://www.cnn.com/2021/01/27/health/regeneron-coronavirus-variants/index.html

 

Quote

 

Coronavirus: Germany to use new antibody-based drug

Health Minister Jens Spahn has said the government has purchased a new drug to help fight COVID-19 amid a vaccine shortage. Germany will be the first EU nation to use the medicine, which was also given to Donald Trump.

Health Minister Jens Spahn told German newspaper Bild am Sonntag that the government had purchased a new antibody-based drug to fight the coronavirus.

"Starting next week, the monoclonal antibodies will be used in Germany as the first country in the EU. Initially in university clinics," he said. "The federal government has bought 200,000 doses for €400 million ($487 million)."

Former US President Donald Trump was treated with this form of antibody treatment after he was infected with the coronavirus last October, Spahn said.

"They act like a passive vaccination. Administering these antibodies in the early stages can help high-risk patients avoid a more serious progression," he added.

Trump, who was briefly hospitalized with the virus, was treated with the REGN-COV2 antibody cocktail from US company Regeneron. 

 

https://www.dw.com/en/coronavirus-germany-to-use-new-antibody-based-drug/a-56328493

Edited January 27, 20215 yr by vememah

ipak nije 8% .... već 6,3%

 

 

Njemci preporucuju tu vakcinu za <65

 

Astra Zeneca

 

 

Quote

"Zato pozivamo sve zainteresovane građane kojima je bio dijagnostifikovan COVID-19, žive na teritoriji Beograda i imaju 18-65 godina da se priključe realizaciji naučnog istraživanja NUTRICOV. Projekat NUTRICOV ispituje kako status vitamina D, cinka i selena, određen ishranom, životnim navikama i naslednom osnovom pojedinca utiče na bolest COVID-19. Rezultati NUTRICOV studije mogu da usmere nauku u pravcu pronalaženja preventivnih strategija koje će pomoći da se bolje zaštitimo ili bar bolje pripremimo za infektivne bolesti poput COVID-19.

Na koji način možete da doprinesete? Sve što treba da uradite je da sa nama podelite informacije o Vašoj ishrani, date podatke o simptomima bolesti COVID-19 koju ste preležali i učestvujete u genetičkim i biohemijskim analizama. Ako niste imali COVID-19, takođe možete da doprinesete tako što ćete ovu informaciju preneti prijateljima za koje znate da su preležali COVID-19 i pozvati ih da se uključe."

https://nutricov.rs/

Edited January 28, 20215 yr by I*m with the pilots

Srela danas nasu babicu, pricali malo o poslu u ovom vremenu. Jako me je iznenadilo kada mi je rekla da ona nije u prioritetnoj listi za vakcinaciju. Nisam uopste razmisljala o tome do danas, ali ni na pamet mi ne bi palo da babice koje obilaze tek sveze porodilje nisu prioritet. Ne znam da li je razlicito za one koje su u porodjajnoj sali, zaboravih da pitam.

Edited January 28, 20215 yr by I*m with the pilots

7 hours ago, barrcode said:

ipak nije 8% .... već 6,3%

 

 

 

Ovo je taj dokument:
https://www.handelsblatt.com/downloads/26863416/2/stiko-entwurf-28-01.

 

Na 32. strani piše da je za oksfordsku vakcinu presek rađen još 4.11. Ne znam zašto nisu koristili novije podatke, sigurno ih ima.

Ali valjda SA varijanta je znatno otpornija

7 hours ago, borris_ said:

Njemci preporucuju tu vakcinu za <65

 

Astra Zeneca 

 

A što je ne bi preporučivali, ima dokazanu efikasnost veću od 70%?

 

Vakcina protiv gripa ima prosečnu efikasnost reda 40-50%.

 

 

https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm

Edited January 28, 20215 yr by vememah

AZN rezultati iz US dolaze za par nedjelja pa ce moci da donesu odluku i za 65+

3 minutes ago, vememah said:

 

A što je ne bi preporučivali, ima dokazanu efikasnost veću od 70%?

 

Vakcina protiv gripa ima prosečnu efikasnost reda 40-50%.

 

 

https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm

Pogresno si me shvatio. Vec sam napiso da mi je ok da se ova vakcina preporuci za <65godina.

 

Ovo  je za kompaniju AstraZeneca i nacin na koji radili fazu 3.

 

Najmanja test grupa je najugrozenija virusom.